Literature DB >> 26449764

Renal extramedullary hematopoiesis: interstitial and glomerular pathology.

Mariam P Alexander1, Samih H Nasr1, Paul J Kurtin2, Edward T Casey3, Loren P Herrera Hernandez1, Mary E Fidler1, Sanjeev Sethi1, Lynn D Cornell1.   

Abstract

Renal extramedullary hematopoiesis is rarely recognized in the antemortem setting. We identified 14 patients with renal extramedullary hematopoiesis on antemortem specimens from 1994 to 2015. The mean age was 68 years (range 47-87 years); males predominated (M:F=9:5). All presented with renal insufficiency, including five (36%) with acute kidney injury. The mean serum creatinine at biopsy was 2.9 mg/dl (range 1.2-7.3 mg/dl). All had proteinuria (mean 7.9 g/24 h; range 0.5-28; n=13), including 9 with ≥3 g/24 h. Renal extramedullary hematopoiesis appeared histologically as an interstitial infiltrate (n=12) and/or a perirenal infiltrate (n=3) or mass-like lesion (n=1). Five were misdiagnosed as interstitial nephritis. Concurrent glomerular disease was prevalent and included fibrillary-like glomerulonephritis (n=3), chronic thrombotic microangiopathy (n=5), focal segmental glomerulosclerosis (n=6), and diabetic glomerulosclerosis (n=2). All patients had an underlying hematologic malignancy: primary myelofibrosis in 9, myeloproliferative neoplasm not otherwise specified in 1, essential thrombocythemia in 1, polycythemia vera in 1, and plasma cell myeloma in 2. Clinical follow-up was available in 12 patients, mean of 29 months (range 4-120 months). In 10 patients for whom treatment history could be obtained, 9 were treated with chemotherapy, and 1 was treated with steroids. The mean creatinine at last follow-up was 2 mg/dl (range 1.2-3.9 mg/dl) (n=9). Ten patients died in the follow-up period from their underlying hematological disease and had persistent renal disease. The two remaining patients had persistent chronic kidney disease. Renal extramedullary hematopoiesis should be considered in the differential diagnosis of interstitial infiltrates, particularly in the presence of a glomerulopathy and a hematologic malignancy.

Entities:  

Mesh:

Year:  2015        PMID: 26449764     DOI: 10.1038/modpathol.2015.117

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  35 in total

Review 1.  Intrarenal extramedullary hematopoiesis as a renal mass in a patient with thalassemia.

Authors:  I Saisorn; S Leewansangtong; S Sukpanichnant; T Ruchutrakool; P Leemanont
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

2.  Extramedullary hematopoiesis in the endometrium.

Authors:  Rosalia M Valeri; Nada Ibrahim; Michael T Sheaff
Journal:  Int J Gynecol Pathol       Date:  2002-04       Impact factor: 2.762

3.  Extramedullary hematopoiesis in the prostate.

Authors:  P A Humphrey; R T Vollmer
Journal:  Am J Surg Pathol       Date:  1991-05       Impact factor: 6.394

4.  Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis.

Authors:  L I Kornblihtt; P S Vassalllu; P G Heller; N R Lago; C L Alvarez; F C Molinas
Journal:  Ann Hematol       Date:  2008-06-25       Impact factor: 3.673

5.  Idiopathic myelofibrosis with extramedullary hematopoiesis in the kidneys.

Authors:  P Schnuelle; R Waldherr; K J Lehmann; J Woenckhaus; W Back; Z Niemir; F J van der Woude
Journal:  Clin Nephrol       Date:  1999-10       Impact factor: 0.975

6.  Nephrotic syndrome associated with agnogenic myeloid metaplasia.

Authors:  Omer Nuri Pamuk; Gülsüm Emel Pamuk; Mehmet Riza Altiparmak; Abdullah Sonsuz; Seyhun Solakoğlu; Isin Kiliçaslan
Journal:  Leuk Lymphoma       Date:  2002-03

7.  Myeloproliferative neoplasms cause glomerulopathy.

Authors:  Samar M Said; Nelson Leung; Sanjeev Sethi; Lynn D Cornell; Mary E Fidler; Joseph P Grande; Sandra Herrmann; Ayalew Tefferi; Vivette D D'Agati; Samih H Nasr
Journal:  Kidney Int       Date:  2011-06-08       Impact factor: 10.612

8.  The Page kidney: a correctable form of arterial hypertension.

Authors:  G Sufrin
Journal:  J Urol       Date:  1975-04       Impact factor: 7.450

9.  Nephrotic syndrome associated with agnogenic myeloid metaplasia.

Authors:  M A Perazella; G K Buller
Journal:  Am J Nephrol       Date:  1994       Impact factor: 3.754

10.  Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Authors:  Cody A Koch; Chin-Yang Li; Ruben A Mesa; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2003-10       Impact factor: 7.616

View more
  9 in total

Review 1.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

2.  Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Authors:  Yasutaka Fukuda; Marito Araki; Kouji Yamamoto; Soji Morishita; Tadaaki Inano; Kyohei Misawa; Tomonori Ochiai; Yoko Edahiro; Misa Imai; Hajime Yasuda; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

3.  WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol       Date:  2017-07-24       Impact factor: 0.975

4.  Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.

Authors:  Marko Lucijanic; Davor Galusic; Ivan Krecak; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Rajko Kusec
Journal:  Ann Hematol       Date:  2020-08-29       Impact factor: 3.673

Review 5.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

6.  Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol Case Stud       Date:  2017-07-24

Review 7.  Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits.

Authors:  Antoine Morel; Marie-Sophie Meuleman; Anissa Moktefi; Vincent Audard
Journal:  Diagnostics (Basel)       Date:  2021-04-15

8.  A case of perirenal extramedullary hematopoiesis in a patient with primary myelofibrosis.

Authors:  Kentaro Imai; Tomonori Aoi; Hiroki Kitai; Nobuhide Endo; Masahiko Fujino; Shizunori Ichida
Journal:  CEN Case Rep       Date:  2017-09-11

9.  Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Authors:  Fermin Person; Sara C Meyer; Helmut Hopfer; Thomas Menter
Journal:  Virchows Arch       Date:  2021-06-23       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.